Physician profile
Jonathan Pai
NPI 1285196105
$5,202.31
in general payments reported to CMS, 2019-2025
41 companies · $1,583 in 2025
The $1,583 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $586 · 2023: $1,325 · 2024: $1,708 · 2025: $1,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,351 · Education: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,351.01 |
| Education | $264.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $514.03 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $497.19 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $451.94 | 2022-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Abbvie INC. | $437.10 | 2023-2025 | |
| Incyte Corporation | $429.64 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Celgene Corporation | $344.24 | 2022-2025 | Reblozyl |
| Emd Serono, INC. | $194.08 | 2023-2025 | Bavencio |
| Sobi, INC | $179.02 | 2022-2025 | |
| Daiichi Sankyo INC. | $173.33 | 2023-2025 | Enhertu, Vanflyta, Datroway |
| Servier Pharmaceuticals LLC | $173.24 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $167.09 | 2023-2024 | Ultomiris |
| Pfizer INC. | $151.82 | 2023-2025 | |
| Janssen Biotech, INC. | $112.66 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $105.60 | 2024-2025 | Imfinzi, Lynparza, Calquence |
| Ipsen Biopharmaceuticals, INC | $101.20 | 2022-2024 | Somatuline Depot, Onivyde |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $97.00 | 2024 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $87.53 | 2022-2025 | Fruzaqla |
| Jazz Pharmaceuticals INC. | $83.39 | 2023-2025 | Rylaze |
| Genentech USA, INC. | $82.81 | 2024-2025 | Polivy, Perjeta, Alecensa |
| Amgen INC. | $73.24 | 2022-2023 | Kyprolis |
| Regeneron Healthcare Solutions, INC. | $70.73 | 2022-2024 | Libtayo |
| Deciphera Pharmaceuticals INC. | $65.64 | 2023-2025 | Qinlock, Tgct |
| Geron Corporation | $58.81 | 2025 | Rytelo |
| Glaxosmithkline, LLC. | $57.93 | 2025 | Jemperli, Zejula, Ojjaara |
| Karyopharm Therapeutics INC. | $54.32 | 2024-2025 | Xpovio |
| Agios Pharmaceuticals, INC. | $47.44 | 2025 | Pyrukynd |
| Eisai INC. | $45.36 | 2024-2025 | |
| Stemline Therapeutics INC. | $40.21 | 2025 | Orserdu |
| Kite Pharma, INC. | $34.06 | 2024 | Yescarta |
| Exelixis INC. | $31.94 | 2025 | Cabometyx |
| Syndax Pharmaceuticals, INC. | $31.67 | 2025 | |
| Genmab U.S., INC. | $29.09 | 2025 | |
| Seagen INC. | $26.96 | 2023 | Tukysa |
| Lilly USA, LLC | $26.80 | 2025 | Verzenio, Jaypirca |
| Baxter Healthcare | $24.99 | 2025 | Perclot |
| Rigel Pharmaceuticals, INC. | $19.76 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Adc Therapeutics America, INC. | $19.65 | 2024 | |
| Coherus Oncology, INC. | $19.27 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $15.26 | 2024 | Opdualag |
| Beigene USA, INC. | $13.56 | 2025 | Brukinsa |
| Puma Biotechnology, INC. | $12.71 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Pai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.